JHVEPhoto / Getty Images Avidity Biosciences is being bought by Novartis in a $12 billion deal. Key Takeaways Novartis is buying Avidity Biosciences in an all-cash deal valued at $12 billion to access Avidity's experimental treatments for neuromuscular diseases. The purchase price of $72 per share is a 46.5% premium to Avidity's closing price Friday. Avidity stock was up more than 40% in midday trading Monday, as were shares of Dyne Therapeutics, which is also developing RNA therapies for neuromuscul ...